Tuesday 15 May |
Amerisur Resources |
Macfarlane Group |
Spirax-Sarco Engineering |
Anglo Pacific Group |
Charles Taylor |
Vitec Group |
IWG |
UBM |
Cairn Energy |
G4S |
Wednesday 16 May |
Indivior |
National Express Group |
Mondi |
Merchants Trust |
Premier Oil |
Chesnara |
Jupiter Fund Management |
Moss Bros |
Coats Group |
Ophir Energy |
Cineworld Group |
Tritax Big Box REIT |
Secure Trust Bank |
Charter Court Financial Services Group |
Utilitywise |
Fenner (re acquisition by Michelin) |
Thursday 17 May |
Just Group |
Hill & Smith Holdings |
Lidco Group |
Fevertree Drinks |
Highcroft Investments |
esure Group |
Foxtons Group |
Hiscox |
Prudential |
Next |
North Midland Construction |
Legal & General Group |
Vectura Group |
Regional REIT |
Staffline Group |
Robert Walters |
Genel Energy |
TI Fluid Systems |
Friday 18 May |
Paddy Power Betfair |
Independent News & Media |
AstraZeneca |
Computacenter |
Clarke (T) |
Petrofac |
John Menzies |
Derwent London |
Hikma Pharmaceuticals |
NEX Group (re acquisition by CME London) |
Monday 21 May |
BP |
Cloudcall Group |
Restore |
4D Pharma |
TBC Bank Group |
Secure Income REIT |
More positive data reported from 4D Pharma trial of 'Blautix'
(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced additional positive data from its completed phase 2 trial of 'LBP Blautix' on Monday, in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D).
Read more